Transfer of p14arf gene in drug-resistant human breast cancer mcf-7/adr cells inhibits proliferation and reduces doxorubicin resistance

Cancer Letters

Volumn 158, Issue 2, 2000, Pages 203-210

  Guo Chang, Fan ^a   Chu Tse, Wu ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Breast cancer; Doxorubicin; Mdr 1; P glycoprotein; P14arf; Tumor suppression

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; PROTEIN; PROTEIN P14ARF;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; P-GLYCOPROTEIN; PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0034295214     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00524-3     Document Type: Article

References (34)

1. D.E. Quelle, F. Zindy, R.A. Ashmun, C.J. Sherr, Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest, Cell 83 (1995) 993-1000.
2. D. Duro, O. Bernard, V. Della Valle, R. Berger, C.-J. Larsen, A new type of p16INK4A/MTS1 gene transcript expressed in B-cell malignancies, Oncogene 11 (1995) 21-29.
3. L. Mao, A. Merlo, G. Bedi, G.I. Shapiro, C.D. Edwards, B.J. Rollins, D. Sidransky, A novel p16INK4A transcript, Cancer Res. 55 (1995) 2995-2997.
4. S. Stone, P. Jiang, P. Dayanath, S.V. Tavtigian, H. Katcher, D. Parry, G. Peter, A. Kamb, Complex structure and regulation of the p16 (mts1) locus, Cancer Res. 55 (1995) 2988-2994.
5. M. Serrano, H. Lee, L. Chin, C. Cordon Cardo, D. Beach, R.A. DePinto, Role of the INK4a locus in tumor suppression and cell mortality, Cell 85 (1996) 27-37.
6. T. Nobori, K. Miura, D.J. Wu, A. Lois, O.M. Takabayashi, D.A. Carson, Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature 368 (1994) 753-756.
7. L.I. Huschtscha, R.R. Reddel, p16(INK4a) and the control of cellular proliferative life span, Carcinogenesis 20 (1999) 921-926.
8. N.E. Sharpless, R.A. DePinho, The INK4A/ARF locus and its two gene products, Curr. Opin. Genet. Dev. 9 (1999) 22-30.
9. L. Chin, J. Pomerantz, R.A. DePinho, The INK4a/ARF tumor suppressor: one gene-two products-two pathways, Trends Biochem. Sci. 23 (1998) 291-296.
10. J. Mitra, C.Y. Daig, K. Somasundarum, W.S. El Deiry, K. Satyamoorthy, M. Herlyn, G.H. Enders, Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a), Mol. Cell. Biol. 19 (1999) 3916-3928.
11. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, C.J. Sherr, Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF, Cell 91 (1997) 649-659.
12. G.C. Fan, L. Lei, J.J. Xie, C.T. Wu, Transfer of p14ARF gene in human tumor cell lines inhibits cell proliferation, Chin. J. Cancer 19 (2000) 104-108.
13. K.D. Robertson, P.A. Jones, Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus, Oncogene 18 (1999) 3810-3820.
14. F.J. Stott, S. Bates, M.C. James, B.B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K.H. Vousden, G. Peters, The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2, EMBO J. 17 (1998) 5001-5014.
15. F. Zindy, C.M. Eischen, D.H. Randle, T. Kamiji, J.L. Cleveland, C.J. Sherr, M.F. Roussel, Myc singleing via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization, Genes Dev. 12 (1998) 2424-2433.
16. E. Stanchina, M.E. McCurrach, F. Zindy, S.Y. Shieh, G. Ferbeyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J. Sherr, S.C. Lowe, E1A signaling to p53 involves the p19ARF tumor suppressor, Genes Dev. 12 (1998) 2434-2442.
17. C.J. Sherr, Tumor surveillance via the ARF-p53 pathway, Genes Dev. 12 (1998) 2984-2991.
18. Y. Zhang, Y. Xiong, W.O. Yarbrough, ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways, Cell 92 (1998) 725-734.
19. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, C.J. Sherr, Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2, Proc. Natl. Acad. Sci. USA 95 (1998) 8292-8297.
20. W. Tao, A.J. Levine, P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2, Proc. Natl. Acad. Sci. USA 96 (1999) 6937-6941.
21. Y. Zhang, Y. Xiong, Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53, Mol. Cell 3 (1999) 579-591.
22. J. Pomerantz, N. Schreiber, N.J. Lieois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.W. Lee, C. Cordon Cardo, R.A. DePinho, The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53, Cell 92 (1998) 713-723.
23. J.D. Weber, L.J. Taylor, M.F. Roussel, C.J. Sherr, D. Bar Sagi, Nucleolar Arf sequesters Mdm2 and activates p53, Nat. Cell Biol. 1 (1999) 20-26.
24. R. Honda, H. Yasuda, Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53, EMBO J. 18 (1999) 22-27.
25. K. Kurokawa, T. Tanaka, J. Kato, p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts, Oncogene 18 (1999) 2718-2727.
26. E.C. Holland, W.P. Hively, V. Gallo, H.E. Varmus, Modeling mutations in the G1 arrest pathway in human gliomas: over-expression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes, Genes Dev. 12 (1998) 3644-3649.
27. I. Utz, V. Gekeler, W. Ise, J. Beck, M. Spitaler, H. Grunicke, J. Hofmann, Protein kinase C isoenzyme, p53, accumulation of Rhodamine 123, Glutathione-S-Transferase, Topoisomerase II and MRP in multidrug resistant cell lines, Anticancer Res. 16 (1996) 289-296.
28. U.S. Stein, W. Walther, M. Lemm, H. Naundorf, I. Fichtner, Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo, Int. J. Cancer 72 (1997) 885-891.
29. J.G. Hall, A.H. Gory, J.G. Gory, Lack of competition of substrates for P-glycoprotein in MCF-7 breast cancer cells overexpressing MDR1, Adv. Enzyme Regul. 39 (1999) 113-128.
30. B. Ogretmen, A.R. Safa, Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells, Oncogene 14 (1997) 499-506.
31. T. Kamijo, E. van de Kamp, M.J. Chong, F. Zindy, J.A. Diehl, C.J. Sherr, P.J. McKinnon, Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function, Cancer Res. 59 (1999) 2464-2469.
32. M. Weller, Predicting response to cancer chemotherapy: the role of p53, Cell Tissue Res. 292 (1998) 435-445.
33. J.V. Thottassery, C.P. Zambetti, K. Arimori, E.G. Schuetz, J.D. Schuetz, P53-dependent regulation of mdr1 gene expression causes selective resistance to chemotherapeutic agents, Proc. Natl. Acad. Sci. USA 94 (1997) 11037-11042.
34. G.C. Fan, C.T. Wu, Y.F. Wang, S.K. Wu, Z.H. Qiu, Effect of human wild-type p53, GM-CSF and B7-1 genes on biological behavior of chemotherapy-resistant tumor cells via recombinant adenoviral vector, Chin. J. Cancer 19 ((1)) (2000) 10-16 (in Chinese).